IFNG and Mendelian susceptibility to mycobacterial diseases: IFN-γ1b treatment has previously been reported in several MSMD patients with normal or residual responses to IFN-γ, but not in the two previously reported patients with AR complete IFN-γ deficiency [28, 34–40].